1
. T cell responses are elicited around 1-2 weeks after infection, but are largely ineffective owing to the early emergence of antigen escape variants of HIV 1 . Recent reports have highlighted the dual role of the innate immune system in early viral control and in contributing to disease pathology. Dendritic cells (DCs) and natural killer (NK) cells are vital mediators of the innate immune system and promote the development of adaptive immune responses. DCs are crucial for activating and conditioning virus-specific T cells, a process that is largely influenced by the preceding innate immune response. NK cells impede the early spread of viruses by producing cytokines and directly killing infected cells. HIV vaccine strategies that use DCs, through either in vitro manipulation of DCs isolated from patients or in vivo targeting of DC subsets, are currently being investigated. The success of these approaches will depend on a proper understanding of how DC biology is affected by HIV-1 infection. NK cells may be crucial for early control of HIV infection and can have important roles in editing the function of DCs, thereby affecting the ability of DCs to prime antiviral effector T cells. This Review focuses on the roles of these two innate cell types during HIV-1 infection.
DCs bridge innate and adaptive immunity Human DCs are rare potent antigen-presenting cells that can be generally divided into myeloid CD11c + 'conventional' DCs (cDCs) or plasmacytoid DCs (pDCs) 2 ( Table 1) . Both subsets specialize in detecting viruses and initiating innate and adaptive immune responses that lead to viral elimination or control. DCs express several receptors for recognizing viruses 3 , including pattern recognition receptors (PRRs) such as the Toll-like receptors (TLRs) and C-type lectins. DCs detect viruses in peripheral tissue sites and, following activation and viral uptake, migrate to draining lymph nodes, where they trigger adaptive immune responses and promote NK cell activation 4 ( Table 1) . Activated cDCs produce cytokines such as interleukin-12 (IL-12), IL-15 and IL-18. IL-12 is crucial for cDCs to induce T helper 1 (T H 1) cell responses, which subsequently promote the potent cytotoxic T lymphocyte (CTL) responses that are necessary for clearing virus-infected cells 5 . Both IL-12 and IL-15 produced by cDCs can activate NK cells 4 (Table 1) . pDCs produce more type I interferons (IFNs) in response to HIV than any other cell type in the body, and stimulate cDCs in a bystander fashion as well as directly activating NK cells 6 . In the following section, we describe recent observations that have been made concerning DC biology and function during HIV-1 infection. Specifically, we focus on how DCs bind and recognize HIV virions, and how DCs are in turn modulated by the virus, ultimately leading to their dysregulation in vivo. The implications of these events underlie the need to develop vaccine strategies that enhance the ability of DCs to prime potent T cell responses that can subvert the potential inhibitory effects of HIV on the immune system.
Binding and recognition of HIV by DCs HIV entry receptors. Binding and internalization of HIV by DCs is mediated by the various HIV entry receptors (which include CD4, CC-chemokine receptor 5 (CCR5) and CXC-chemokine receptor 4 (CXCR4)). Birbeck granule a membrane-bound structure that is found in the cytoplasm of langerhans cells. These granules are rod-or tennis racket-shaped with a central linear density. Their formation is induced by langerin, an endocytic C-type lectin receptor that is specific to langerhans cells.
other chemokine receptors, including CCR3, CCR8, CCR9 and CXCR6 (Refs 7, 8) , have also been suggested to participate in HIV-1 entry. In addition, cDCs express C-type lectins that bind to HIV, including DC-specific ICAm3-grabbing non-integrin (DC-SIGN), langerin (also known as CLeC4K or CD207) and DC immunoreceptor (DCIR; also known as CLeC4A) 7, 9 (Table 1) .
expression of these receptors varies based on cDC subtype, localization and activation state. Although pDCs express C-type lectins, such as blood DC antigen 2 (BDCA2; also known as CLeC4C), binding of HIV to pDCs is generally mediated by interaction of the HIV gp120 envelope protein with CD4 (Ref. 10) ( Table 1) .
The identities of the receptors involved in virus-cDC interactions can affect virus fate. Binding of HIV to DC-SIGN through its gp120 envelope protein leads to internalization of the virus into DC early endosomal compartments, where it is not degraded. This may enable DCs to deliver intact HIV virions to draining lymph nodes, where DC-T cell interactions could promote infection of T cells through viral synapses and/ or cell-cell fusion. However, the contribution of this mode of transmission has been called into question, as the transfer of HIV-1 to T cells can occur independently of DC-SIGN 11 . Conversely, another report has highlighted how interaction of HIV with DC-SIGN may be important for transmission of HIV. Clusterin in semen is glycosylated differently to clusterin in blood and specifically blocks the HIV-DC-SIGN interaction, thereby preventing HIV transmission to CD4 + T cells. The different efficacies with which these two forms of clusterin block HIV-DC-SIGN interactions may explain why sexual exposure to HIV is less likely to result in infection than blood-borne exposure 12 . DCIR was also recently found to bind to HIV virions and, in a similar way to DC-SIGN, promotes transmission of infectious virus to CD4 + T cells 13 . The C-type lectin langerin, which can bind and internalize HIV, is expressed by epidermal Langerhans cells, and migratory Langerhans cells are believed to enhance sexually transmitted HIV infection by promoting the spread of the virus to T cells in draining lymph nodes. In contrast to DC-SIGN-mediated internalization, HIV internalized through langerin is trafficked to birbeck granules, where the virus is rapidly degraded 14 ; this suggests that Langerhans cells also function as a barrier to HIV infection. However, high viral concentrations enable langerin-independent internalization of HIV by Langerhans cells, resulting in the transport of intact HIV to T cells by migratory Langerhans cells. In accordance with this, others have shown that in vitro-derived Langerhans cells can transmit infectious HIV to T cells 15 . Thus, the fate of HIV varies depending on the particular cDC receptors used to bind the virus, and this emphasizes how different DC subsets can either contribute to or hinder HIV infection. . This is surprising considering that blood cDCs express TLR7 and TLR8, both of which can be activated by HIV-derived single-stranded RNA. one possible explanation is low viral replication within cDCs; only 1-3% of cultured DCs become infected in vitro, and circulating blood DCs isolated from patients with HIV do not appear to be infected with the virus 20, 21 . A recent study using a pseudotyped virus that lacked HIV envelope protein showed that when this strain of HIV-1 carries the vpx gene, infection of DCs promotes their maturation and production of type I IFNs, and facilitates antiviral T cell immunity. This response is mediated by interaction of newly synthesized HIV-1 capsid with cellular cyclophilin A (also known as PPIase A) and activation of the type I IFN-inducing transcription factor IRF3 through an unknown cytoplasmic sensor 22 . Thus, it is possible that there are too few virions within HIV-1-exposed cDCs to trigger TLR signalling, or that vpx is essential for this interaction. However, although viral replication in pDCs is also low, pDCs rapidly respond to HIV-1 through TLR7. Therefore, another explanation is that HIV interaction with C-type lectins may abrogate subsequent TLR responsiveness in cDCs. HIV, in a similar way to Mycobacterium spp., has been implicated in inhibiting TLR stimulation of cDCs through its interactions with DC-SIGN 23 and this is discussed in more detail below.
Can TLR signalling promote HIV replication in DCs?
De novo replication of integrated HIV-1 in immature cDCs can be initiated by TLR8-and DC-SIGNmediated signal transduction events. HIV is targeted to TLR8-containing endosomal compartments by DC-SIGN, and this initiates the transcription of integrated HIV-1 DNA through TLR8 activation and subsequent nuclear factor-κB (NF-κB) signalling 24 . The binding of gp120 to DC-SIGN leads to RAF1-mediated phosphorylation of the p65 subunit of NF-κB, thereby permitting transcription elongation of nascent HIV-1 transcripts and productive transcription within infected DCs 24 . Thus, ligation of both TLR8 and DC-SIGN is required for the induction of signal transduction pathways that promote the synthesis of complete viral transcripts from integrated proviral DNA. Co-infection with Candida albicans or Mycobacterium tuberculosis also triggers RAF1-dependent phosphorylation, suggesting that co-infection could enhance the productive transcription of HIV 24 . Although this in vitro work argues for a role of TLR8 in promoting HIV replication in cDCs, it is unclear whether this is a physiological mechanism for productive infection in cDCs, as replication within cDCs is very low. However, it raises the issue of whether the use of TLR8 agonists as immunotherapeutic adjuvants might increase productive replication within cDCs containing integrated HIV-1.
Autophagy and HIV recognition. autophagy leads to the delivery of cytosolic components (such as signalling molecules and damaged organelles) to lysosomal compartments, which contain PRRs 25 . Following HIV-1 infection, fusion between endosomes and autophagosomes is inhibited, thereby preventing autophagy-mediated viral degradation 26 . This inhibition occurs through activation of mammalian target of rapamycin (mToR), a serine/ threonine kinase that is a negative regulator of autophagy. In accordance with inhibition of autophagy, HIV-1 replication in DCs leads to decreased cathepsin activity in these cells, possibly owing to a blockade of lysosomal fusion, which is necessary for cathepsin activation. This results in enhanced survival of HIV-1 in phagosomes and decreased presentation of viral antigens [27] [28] [29] .
In contrast to the aforementioned study, which showed that HIV can activate TLR8, HIV-mediated inhibition of autophagy was shown by others to inhibit DC responsiveness to the classical TLR4 and TLR8 agonists lipopolysaccharide (LPS) and single-stranded RNA 26 . one explanation for this discrepancy may be that activation of TLR8 by HIV precedes autophagy inhibition. Alternatively, selective blockade of autophagosomes by HIV may depend on the particular HIV receptor used for viral entry. Clearly, additional studies are necessary to understand how HIV-1 can modulate cDC responsiveness to TLR agonists. It will also be important to determine how HIV affects different blood cDC subtypes, such as the newly described BDCA3 + (also known as CD141 + ) blood DC subset 30 .
Dysregulation of DCs in HIV-1 infection
Decreased DC frequency. HIV-1 infection leads to a progressive reduction in blood DC numbers (both cDCs and pDCs), which correlates with increasing plasma virus load and disease progression 31 . This decrease in DC frequency occurs early during acute HIV infection and is sustained in the later stages of infection 20 . Patients with chronic HIV infection also have fewer blood DCs compared with uninfected controls 20, 31 . Direct infection of DCs has been suggested to be responsible for decreased DC frequency during HIV infection 31 . Several studies have evaluated whether DCs from the blood of patients with chronic HIV-1 infection are infected with HIV, with some showing evidence of infection but others suggesting that no infection occurs 21, 32 . Given the low level of HIV-infected DCs, it is unlikely that direct infection can adequately explain the decreased DC frequency in the blood of patients with HIV.
Instead, the decline in blood DC frequency during viral infection may be due to indirect mechanisms. Aberrant IFNα production during HIV infection may impede the differentiation of cDCs from monocytes 33 or other precursors. Also, DCs from patients with HIV show increased apoptosis compared with DCs from uninfected individuals 34 . A third possibility is that decreased DC frequencies in the blood may be due to the redistribution of DCs to secondary lymphoid organs. Indeed, several groups have reported an increase in pDCs in the lymph nodes 35, 36 and spleens 37 of patients with HIV. The overall functional capacity of DCs found in the secondary lymphoid organs of patients with HIV remains to be adequately evaluated.
Finke et al. 38 reported that cDC numbers returned to normal levels following antiretroviral therapy (ART). Another recent study showed no effect of primary HIV-1 infection on cDC levels, and although pDC and CD4 + T cell numbers were reduced, they were restored following ART 39 . The differential restoration of cDC and pDC numbers may be due to multiple components of the immune system going awry beyond repair in the chronic phase of infection. Altogether, these data warrant a closer scrutiny of the functional status of DC subsets during the immune recovery associated with ART.
Altered cDC function.
Although there is an overall consensus that blood DC numbers decline during HIV infection, it is still unclear whether DCs from patients with HIV are functionally impaired. As indicated previously, HIV interaction with DC-SIGN might negatively affect TLR-induced activation of cDCs. Accordingly, HIV-1 infection interferes with the maturation of blood cDCs and monocyte-derived DCs in response to in vitro activation stimuli 28, 40 . other studies have reported that cDCs are not functionally defective following HIV exposure 20, 21 , showing that ex vivo isolated cDCs from patients with acute HIV infection may even be hyperresponsive to TLR stimulation 20 and produce increased levels of IL-12, IL-6, TNF and CCL3 (also known as mIP1α) compared with cDCs from uninfected controls. By contrast, compared to pDCs isolated from uninfected controls, pDCs isolated from patients with acute HIV infection can show decreased IFNα production during the early stages of infection, but increased IFNα production at later stages of infection 20 . These discordant results may result from the limitations of analysing isolated DCs ex vivo. modulation of DC function in vivo may not necessarily be a result of direct HIV exposure, but could instead be due to factors that are produced by the host in response to infection. moreover, depending on the stage of HIV infection, DCs may be affected by the microenvironment. For example, during chronic HIV infection, monocytes have been shown to upregulate programmed cell death protein 1 (PD1) and produce IL-10, possibly in response to the high levels of gut-derived microbial products that are present in the plasma of these patients 41 . Circulating LPS and other pathogen-derived factors have been implicated in promoting the chronic immune activation that is observed during HIV infection, either by direct activation of DCs or indirectly through stimulation of cells such as macrophages 42 . Such stimuli may lead to partial maturation of cDCs in vivo, making these cells tolerant to subsequent stimuli ex vivo. Accordingly, several reports have indicated that cDCs from chronically infected patients are less efficient at stimulating T cell activation than cells from uninfected individuals 31, 40 . understanding exactly how cDCs are functionally impaired during HIV infection is crucial for effective HIV vaccine design. This is especially true if functional impairment of DCs results from bystander mechanisms during HIV infection, as these mechanisms are likely to impede most DC-targeting approaches, including the reintroduction of ex vivo-manipulated DCs into patients.
Altered pDC function.
As with cDC function, it is unclear whether pDC function is impaired during HIV infection. Several groups have argued that type I IFN production by blood pDCs is attenuated during both acute and chronic HIV infection 43, 44 , whereas others have indicated that circulating pDCs in patients with HIV viraemia show a normal type I IFN response 45 . In the former case, it is possible that circulating pDCs were activated in vivo by HIV before isolation and were, therefore, hyporesponsive to a secondary stimulus delivered ex vivo. Consistent with this, activation markers are upregulated by blood pDCs during acute HIV infection, suggesting that these pDCs have responded to the virus in vivo 20 . Furthermore, IFN-producing pDCs accumulate in the draining lymph nodes of patients with HIV 35, 36 , although these pDCs are prone to apoptosis 34, 36 . Nonetheless, evidence is emerging that pDCs have a crucial role in the immune dysregulation that leads to the development of AIDS.
pDCs that are exposed to HIV upregulate the enzyme indoleamine 2,3-dioxygenase (IDo), which metabolizes tryptophan to kynurenine, and this upregulation is dependent on the gp120-CD4 interaction. Through expression of IDo, pDCs promote the differentiation of naive T cells into regulatory T (T Reg ) cells, which suppress effector T cell activation 46 . It remains to be elucidated whether increased frequencies of T Reg cells prevent effective HIV-specific adaptive immune responses and exacerbate HIV-associated pathology, or whether T Reg cells increase as a result of chronic immune activation in an effort to limit associated immunopathology. By promoting T Reg cell responses, pDCs may be responsible for the decrease in T H 17 cells that occurs during HIV infection 47 ; this decrease is thought to lead to the loss of gut integrity and microbial translocation in patients with HIV 42 .
Response to HIV-1 in humans: an overkill? uncontrolled and persistent inflammation contributes to the pathology that is associated with HIV infection. IFNα-producing pDCs can contribute to the T cell loss that is characteristic of patients with AIDS by upregulating CD4 + T cell expression of the pro-apoptotic molecules TNF-related apoptosis-inducing ligand (TRAIL; also known as TNFSF10), death receptor 5 (DR5; also known as TNFRSF10B), CD95 (also known as FAS) and CD95 ligand (CD95L; also known as FASL) 48, 49 . This may lead to the apoptosis of uninfected CD4 + T cells and promote generalized CD4 + T cell loss. Interestingly, HIV-infected women are almost two times more likely to develop AIDS than HIV-infected men with similar viral loads, and this may be because activated pDCs from HIV-infected women produce more type I IFNs than pDCs from HIV-infected men 50 . Studies of non-human primate models of simian immunodeficiency virus (SIV) infection support the idea that pDCs have pathological roles. Comparing SIV infection in African green monkeys (Cercopithecus aethiops), sooty mangabeys (Cercocebus atys) and macaques (Macaca sp.), it was shown that SIV infection in macaques progresses to AIDS at a rate similar to that in HIV-1-infected humans 51 . African green monkeys and sooty mangabeys, both of which are natural hosts for SIV, do not develop AIDS despite showing high levels of virus replication 52 . Attenuated type I IFN responses are believed to contribute to the lack of SIV-induced immune pathology in sooty mangabeys 53 . Gene profiling has shown that in both non-pathogenic models (African green monkeys and sooty mangabeys) and pathogenic models (macaques) of SIV infection there is a comparable IFN-inducible response to acute SIV infection, but only in pathogenic models is this IFN response maintained during chronic infection 54, 55 .
Additional data from non-human primate models suggests that pDCs can facilitate HIV infection. In the vaginal mucosa of macaques, an initial founder population of T cells becomes infected with SIV but the recruitment of additional target T cells is required for viral spread. It was shown that an early influx of activated pDCs occurs at the initial site of SIV infection and these cells subsequently recruit T cells by secreting chemokines such as CCL5 (also known as RANTeS) 56 . As mentioned above, HIV-exposed pDCs can promote the development of T Reg cells, and these may prevent the induction of effector T cells by inhibiting cDC activation. Thus pDCs may promote the widespread dysregulation of DC function that occurs during HIV infection (fIG. 1) . Furthermore, as DCs can promote NK cell activation, DC dysfunction may contribute to dysregulated NK cell activity during HIV infection. This is discussed in more detail below.
NK cells in HIV-1 infection NK cells and their receptors. NK cells promote antiviral and antitumour immunity 57 by producing proinflammatory cytokines and by lysing infected or transformed cells. In addition, NK cells interact with T cells and DCs to shape the magnitude and quality of adaptive immune responses 58, 59 . To date, no specific NK cell receptors that directly recognize HIV-1-infected cells have been identified, and the NK cell response to HIV-1-infected cells appears to be regulated by the balance of inhibitory and activating signals delivered to NK cells by these Granzyme A a member of a family of serine proteinases that are found, primarily, in the cytoplasmic granules of cytotoxic T lymphocytes and natural killer cells. Granzymes enter target cells through perforin pores, then cleave and activate intracellular caspases to initiate target cell apoptosis.
infected cells. Below, we discuss the mechanisms by which NK cell receptors determine NK cell function in response to viral infections, with a particular focus on HIV-1. NK cell responses are induced against cells that lack expression of the mHC class I molecules that bind NK cell inhibitory receptors 60 (known as 'missing self ' recognition) or by cells that overexpress ligands for NK cell activating receptors. In addition to their role in controlling NK cell effector functions, cognate interactions between inhibitory receptors and their ligands during NK cell development confer both self-tolerance and functionality to NK cells, a process termed 'licensing' (bOX 1).
The most frequently studied inhibitory receptors include the highly polymorphic killer cell immunoglobulin-like receptors (KIRs), which are specific for classical mHC class I molecules, and the non-polymorphic CD94-NKG2A receptor that recognizes the non-classical mHC molecule HLA-e. NK cell activating receptors include NKG2D, activating members of the KIR family, the natural cytotoxicity receptors (NCRs) and the Fcγ receptor CD16. A comprehensive list of inhibitory and activating receptors expressed on NK cells is beyond the scope of this Review and is summarized elsewhere 61 . most NK cells in the peripheral circulation (approximately 90%) are CD56 low , constitutively produce high numbers of cytolytic granules and have the capacity to spontaneously lyse target cells in the absence of prior sensitization. CD56 low NK cells express abundant levels of KIRs, C-type lectins and NCRs, and are thought to be functionally and phenotypically mature cells. The remaining 10% of circulating NK cells are CD56 hi and are often referred to as the 'immunoregulatory' NK cell subset as they are poorly cytotoxic, but following stimulation they secrete large amounts of pro-inflammatory cytokines.
CD56
hi NK cells express high levels of C-type lectins and NCRs, but have low-level or no expression of KIRs. Although originally thought to be distinct cell lineages, it is now believed that these two NK cell subsets represent different stages of NK cell maturation, with CD56 hi NK cells being less mature than CD56 low NK cells 62, 63 . In addition, a third population of NK cells has been described, consisting of CD56 -cells that accumulate during chronic viral infections [64] [65] [66] . These CD56 -NK cells express a similar receptor profile to CD56 low NK cells, but are poorly cytotoxic and do not secrete cytokines. However, cord blood CD3 -CD56 -NK cells appear to be functionally competent 67 , suggesting differences in the differentiation status of these phenotypically similar NK cell subsets.
NK cells and the antiviral response. Several mechanisms have been proposed for NK cell-mediated recognition of HIV-1-infected cells (fIG. 2) . NK cells may be able to detect HIV-infected cells either directly through receptormediated interactions that have not yet been identified or indirectly following antibody-mediated cross-linking of CD16 (an Fc receptor for IgG). NK cell responses to HIV-1-derived peptides have also been observed, although whether these responses are mediated through CD16 or other NK cell receptors remains to be elucidated 68, 69 . Thus, identification of receptors that mediate NK cell recognition of HIV-1 remains an important research topic.
A number of studies have suggested that HIV-1 uses specific strategies to evade NK cells. The HIV protein Nef (negative factor) is known to selectively downregulate expression of HLA-A and HLA-B, but not HLA-C or HLA-e, in infected cells. This allows HIV to evade CTL responses, which are largely directed against HLA-Aand HLA-B-restricted epitopes, and prevent the killing of HIV-infected cells by NK cells, which express inhibitory receptors that bind to HLA-C and/or HLA-e [70] [71] [72] . Furthermore, Nef can impair NK cell activity by downregulating the expression of NKG2D ligands (specifically mICA (mHC class I polypeptide-related sequence A), uLBP1 (also known as N2DL1) and uLBP2 (also known as N2DL2)) on infected cells 73 .
Altered NK cell phenotype and function during HIV-1 infection.
HIV-1 infection is associated with a functional impairment of NK cells that is evident early after infection and continues during disease progression. There is an inverse correlation between viraemia and NK cellmediated suppression of HIV-1 replication, and this may be attributed to several possible mechanisms 74 . First, peripheral NK cells in HIV-1-infected individuals have decreased intracellular stores of perforin and granzyme a, and this may account for the decreased cytotoxic capacity of NK cells 75 . Persistent HIV-1 viraemia has also been shown to result in aberrant expression of several inhibitory and activating NK cell surface receptors. Lower expression of NCRs is associated with the decreased in vitro cytotoxicity of NK cells from HIV-infected individuals 76 , and this may affect NK cell-mediated clearance of virus-infected cells in vivo. However, in other studies, NCR-mediated NK cell activation has been suggested to contribute to pathology by promoting the loss of uninfected CD4 +
Box 1 | NK cell licensing
Natural killer (NK) cell inhibitory receptors for self MHC class I molecules have important roles in controlling the NK cell response to potential target cells. More recently, it has been demonstrated that these receptors ensure NK cell tolerance towards self. Studies in humans and mice have shown that during development NK cells undergo an education process, in which MHC class I-specific inhibitory receptors are involved in the calibration of NK cell effector functions 97, 99 . Engagement of these receptors with MHC class I molecules provides a positive signal to NK cells that leads to licensing of fully competent mature peripheral NK cells. These mature NK cells can sense and lyse autologous cells that have downregulated their expression of MHC class I molecules 97 . NK cells that fail to undergo this education process, owing to a lack of MHC-specific inhibitory receptor engagement, are unlicensed and have a reduced (but not absent) functional activity compared with licensed NK cells [97] [98] [99] . Thus, two major types of self-tolerant NK cells exist with regard to MHC class I: licensed NK cells, which are self-tolerant because they express inhibitory receptors for self; and unlicensed NK cells, which are also self-tolerant as they are not functionally competent. NK cell licensing does not seem to be an 'on-off' switch, but rather a dynamic and quantitative process 125, 126 . The strength of the interaction between inhibitory MHC class I-specific receptors and their cognate MHC class I molecules appears to be proportional to the level of functional responsiveness. NK cells licensed on stronger inhibitory receptor-MHC interactions respond with increased strength and frequency than NK cells licensed on weaker inhibitory signals 125 . Indeed, a hierarchy of NK cell responses to MHC class I-negative cells has been observed that is proportional to the number of different killer cell immunoglobulin-like receptors (KIRs) for self-HLA molecules that are expressed by the NK cell. Certain KIR and HLA alleles are also associated with more responsive NK cells 100, 127 , suggesting that KIR-HLA combinations can differentially affect NK cell effector capacities. 77 . Therefore, the role of NCRs in controlling or contributing to HIV-1 pathology is currently not understood and further investigation is required. Second, a significant proportion (15-25%) of NK cells in the peripheral circulation of HIV-1-infected individuals express some markers of activated NK cells (for example, HLA-DR and CD69) but not others (for example, CD25 and NKp44 (also known as NCR2)) 78 . This suggests that there is an incomplete activation of NK cells in these individuals, and this may be due to chronic stimulation resulting in NK cell exhaustion and anergy. In addition, although overall NK cell numbers are unchanged during HIV infection, infected individuals have fewer CD3 -
T cells during HIV infection

CD56
+ NK cells and show expansion of the functionally anergic CD3 -
-NK cell subset 64, 65 . HIV-1 infection has also been associated with an expansion of NK cell populations that express the activating NKG2C receptor and decreased expression of the inhibitory NKG2A receptor (predominantly on CD56 low NK cells) 79 . This may alter the balance of NK cell responses towards activation. NKG2C is functional in HIV-positive individuals 80 ; however, it is not known how NKG2C functions in HIV infection in the context of diminished NCR-mediated responses. An increase in circulating NKG2C + NK cells in healthy individuals correlates with cytomegalovirus (CmV)-seropositive status 79 , and it is possible that the expansion of NKG2C + NK cell populations during HIV-1 infection may be a result of CmV reactivation in HIV-1-infected individuals. Indeed, perturbation of the NK cell compartment during HIV-1 infection may have serious consequences for protection from opportunistic infections.
Finally, NK cells that express CD4 and CXCR4 can be infected with HIV-1 in vitro, resulting in altered function 81 . This suggests that CD4 + NK cells may be a reservoir for HIV-1 in vivo, and further investigation is required to explore this possibility.
KIRs and HLA molecules in HIV infection early studies showed that the control of HIV replication is associated with the expression of certain HLA-B alleles that have the Bw4 epitope 82 , including HLA-B*57 and HLA-B*27. These molecules serve as ligands for the NK cell inhibitory receptor KIR3DL1 and as putative ligands for the NK cell activating receptor KIR3DS1 (fIG. 2) .
KIR3DS1 and HLA-Bw4-80I. martin et al. 83 first demonstrated the impact of KIRs and HLA molecules on the outcome of HIV infection. The first study to demonstrate a link between expression of KIR and HLA molecules and the outcome of HIV infection showed that individuals expressing KIR3DS1 in conjunction with HLA-Bw4-80I alleles (HLA-Bw4 alleles that have an isoleucine residue at position 80) have a slower progression to AIDS than individuals that express either one or neither of these molecules. These findings were supported by studies demonstrating that KIR3DS1 + NK cells preferentially expand during primary HIV-1 infection in HLA-Bw4-80I + subjects 84 and efficiently suppress HIV-1 replication in HLA-Bw4-80I + target cells 85 . Furthermore, KIR3DS1 expression has been associated with enhanced NK cell function during primary HIV-1 infection 86 , and the proportion of individuals homozygous for KIR3DS1 was found to be higher in a cohort of HIV-1-exposed but persistently uninfected individuals than in a group with primary HIV-1 infection 87 . However, studies aimed at demonstrating a direct interaction between KIR3DS1 and HLA-Bw4-80I have not shown such interactions 88, 89 . Two hypotheses are proposed in the literature. First, KIR3DS1 may recognize HLA-Bw4-80I in the presence of HLA-presented viral peptides or stress-induced self peptides 90 . Indeed HIV-1 infection has been shown to uniquely alter the presentation of host-encoded peptides by mHC class I molecules 91 . Second, recognition of HLA-Bw4-80I by KIR3DS1 might require an additional cellular protein that is expressed during HIV-1 infection. This hypothesis is supported by evidence from murine cytomegalovirus (mCmV) infection, in which the NK cell activating receptor Ly49P was shown to interact with the mouse mHC molecule H2-D k and mediated recognition of mCmV-infected cells only in the presence of an additional, as-yet-undefined protein 92, 93 . KIR3DL1 and HLA-Bw4-80I. Certain alleles of the inhibitory receptor KIR3DL1 have been shown to provide protection against HIV-1 disease progression 94 . KIR3DL1 is highly polymorphic, and different alleles result in different levels of KIR3DL1 protein expression on NK cells 95, 96 . A genetic study on a large cohort of HIV-1-infected individuals revealed that individuals co-expressing high levels of KIR3DL1 and HLA-Bw4-80I had slower HIV-1 disease progression than individuals expressing low levels of both KIR3DL1 and HLA-Bw4-80I 94 . Furthermore, KIR3DL1 + NK cell populations are expanded in HIV-positive individuals who express HLA-Bw4-80I, highlighting the importance of this receptor-ligand interaction in HIV-1 infection 84 . These data showing a protective effect for an inhibitory KIR in HIV infection seem to contradict previous reports, which suggested that NK cell activation is protective during HIV infection. However, this discrepancy could be explained by the interactions of KIRs with HLA molecules during NK cell development. As described in bOX 1, developing NK cells undergo a licensing process, in which engagement of inhibitory KIRs by HLA molecules arms NK cells with functional capacity [97] [98] [99] . The strength of interaction between inhibitory KIRs and HLA molecules at this licensing step proportionately enhances later functional capacity. Indeed, studies have shown that KIR3DL1 + NK cells from individuals homozygous for HLA-Bw4 respond more potently to mHC class I-negative cells than NK cells from individuals expressing only one copy or no copies of HLA-Bw4 (Ref. 100). KIR3DL1
hi NK cells licensed on strong inhibitory signals would therefore respond more strongly to Nef-mediated downregulation of HLA-Bw4 than KIR3DL1 low NK cells. Interestingly, protection against HIV-1 disease progression was also observed in individuals with the KIR3DL1*004 allotype of KIR3DL1 that is not expressed on the cell surface, but detected intracellularly 94 . The mechanism behind this protection is unknown but suggests a role for intracellular KIR-HLA interactions in modulating antiviral immunity.
NK cell licensing might also explain the protective effect of a single nucleotide polymorphism (SNP) that was recently identified in a genome-wide association study 101 . In this study, a dimorphism 35 kb upstream of the HLA-C locus that is associated with higher levels of HLA-C mRNA and surface expression was shown to be associated with better control of HIV-1 viraemia 101, 102 . It is possible that during NK cell development, the interaction of NK cells expressing inhibitory KIR2D receptors with cells expressing high levels of HLA-C (the ligand for KIR2D receptors) may promote the functional capacity of these NK cells.
In summary, recent genetic and functional studies have shown a protective effect for certain KIRs and HLA molecules during HIV-1 disease progression. The mechanisms underlying protection are thought to involve increased NK cell activity against HIV-1-infected cells; however, no data currently exist regarding the role of NK cells during HIV-1 infection in vivo. A better understanding of the functions of NK cells during HIV-1 infection will be required in order to harness these important innate effector cells in vaccineinduced responses, particularly in the context of the recent description of NK cell-mediated recall responses in mice 103, 104 .
DC-NK cell crosstalk in HIV infection
In addition to their own antiviral functions, NK cells can regulate antiviral immunity by modulating DC function 58, [105] [106] [107] [108] [109] [110] . Crosstalk between NK cells and DCs results in activation of both cell types, with DCs upregulating NK cell effector functions and NK cells inducing further maturation of DCs (fIG. 3) . Fernandez et al. 58 initially showed that DCs can promote NK cell activity against tumours in vivo, and several subsequent studies have explored DC-mediated 'priming' of NK cells 4, 111 . Both cytokine production and cell-cell interactions have been found to be involved in this process. Cytokines produced by cDCs, such as IL-12 and IL-18, can promote NK cell production of IFNγ in vitro 4, 106, 108, 111 , and pDC production of type I IFNs, as well as cell-cell contact, is required to promote NK cell proliferation and cytotoxicity 58, 105, 107, 108 (fIG. 3) .
Activated NK cells can boost ongoing adaptive responses by producing IFNγ, which promotes T H 1 cell polarization 105, 109 . Reciprocally, NK cell-mediated activation of DCs has been shown to promote the differentiation of DCs that are more capable of inducing efficient CTL responses 110 . Furthermore, NK cell-mediated lysis of virus-infected cells can provide a source of apoptotic bodies for uptake by DCs; this promotes DC maturation and the presentation of viral antigens to T cells.
NK cells can also kill immature DCs in a process referred to as 'DC editing' 111 . In vitro studies have demonstrated that a low ratio of NK cells to immature DCs promotes DC maturation, whereas a higher NK cell to immature DC ratio can result in NK cell-mediated killing of DCs 110 . This editing process is dependent on NK cell expression of NKp30 (also known as NCR3) 111 , and seems to be mediated by NK cell subsets that express CD94-NKG2A but lack inhibitory KIRs . Furthermore, the anergic CD56 -NK cells that accumulate during progressive HIV-1 infection do not produce IFNγ and TNF following stimulation with mHC-devoid target cells, decreasing their ability to promote DC activation 64, 65 . NK cell-mediated DC editing is also severely compromised during progressive HIV-1 infection, and NK cells from individuals with chronic HIV-1 infection show a decreased ability to kill immature DCs 114 . The defect appears to be largely due to an increase in the proportion of CD56 -NK cells with impaired NKp30 function 115 . The precise mechanisms by which HIV-1 impairs NK cell and DC crosstalk remain to be fully elucidated. effects of HIV-expressed Nef and Tat (transactivator of transcription) on DCs and NK cells have been described 116, 117 .
γ γ HIV-1-infected DCs become resistant to NK cellmediated lysis, and this is associated with the upregulation of cell death inhibitors in infected DCs. These inhibitors are upregulated by the high-mobility group box 1 protein (HmGB1) and protect HIV-1-infected DCs from TRAIL-dependent apoptosis 118 . Furthermore, crosstalk with NK cells was found to promote viral replication in HIV-1-infected DCs, but this could be prevented by blocking HmGB1 activity 119 . In addition, increased production of IL-10 during HIV-1 infection can protect immature DCs from NK cell-mediated lysis, resulting in accumulation of partially mature, poorly immunogenic DCs in the lymph nodes of infected individuals 120 . overall, the dysregulated crosstalk that occurs between NK cells and DCs during progressive HIV-1 infection appears to be a consequence of the impairment of both DC and NK cell functions (fIG. 3) . Given the crucial role of DCs in determining the quality of the adaptive immune response to infections, this compromised editing of DC function by NK cells during HIV-1 infection might have significant consequences for the antiviral T and B cell responses. In order to develop interventions aimed at enhancing immunity to HIV-1, further research is required to better understand the molecular mechanisms involved in NK cell-DC crosstalk and how this crosstalk is disrupted during infection with HIV-1.
Harnessing DCs and NK cells for vaccination
Although HIV-1 infection is considered to be a chronic condition, immune dysregulation can occur early in infection and affect subsequent disease progression. Given the complexity of HIV infection, it remains unclear how the innate immune system can be harnessed to induce effective T and B cell-mediated protective immunity. understanding how DCs and NK cells are affected during HIV infection may provide new targets for vaccine design or even therapeutic modulation of disease. Administration of myeloid DCs that have been pre-treated with inactivated HIV enhances immune control of HIV in patients 121 , suggesting that functionally intact antigen-presenting cells are required to limit viral replication. Adjuvants and vaccine vectors that target cDCs and pDCs simultaneously could promote adaptive immunity and limit T Reg cell induction in order to control virus entry at mucosal sites, as well as systemically 122, 123 . For example, the approach used in a recent vaccine trial in Thailand (which used an HIV envelope immunogen and a canarypox virus-HIV vector) could be improved by using DC-targeted adjuvants and superior vectors in a 'prime-boost strategy' .
Given the speed with which HIV gains entry into cells, innate defences need to be rapidly mobilized. DCs could be targeted to activate specific NK cells and promote their cytolytic functions. epidemiological data have indicated that certain NK receptors, such as KIR3DS1, are important for controlling HIV disease 83 , and in mouse models, NK cells can develop into protective virus-specific memory cells 103, 124 . Therefore, the development of DC-based vaccine strategies that elicit HIV-specific NK cell responses and stimulate the production of memory cells may be crucial for the success of future vaccines. Finally, pDCs are emerging as a population with important roles in contributing to HIV-induced pathology. As such, vaccine strategies that aim to promote cDC and NK cell responses during HIV infection would have to be balanced to prevent any deleterious consequences of immune activation. 
